ALZHEIMER’S DISEASE: AN INTRODUCTION TO THE THERAPEUTIC ROLE OF METAL CHELATORS COUPLED WITH NANOPARTICLES
*Sanjukta Misra
Abstract
Alzheimer�s disease (AD) is a devastating neurodegenerative disease
with progressive and irreversible damage to thought, memory, and
language. The ravaging effects of the disease call for efforts to
prevent, forestall, and reverse the disease. Unfortunately, despite
much interest, currently available FDA-approved drugs target towards
managing cognitive symptoms and fall tremendously sort as adequate
means of therapeutic management. Although the etiology of AD is
incompletely understood, great effort has been made to better
understand the disease�s pathogenesis and to develop more effective
therapeutic agent. Oxidative damage mediated by metals is likely a
significant contributor since metal such as iron, aluminium, zinc, and
copper are increased in brain tissue of AD patients and create a prooxidative
environment. This metal dysregulation may represent a
therapeutic target for AD. Metal chelation therapy through the use of
nanoparticles, an alternative means of drug delivery to brain, is
highlighted here, which may provide insights into the mechanisms of AD pathophysiology
and may prove useful in treating metal-associated neurodegenerative diseases. However this
promising approach is at its very early stage of development and, therefore more studies
should be undertaken to demonstrate the protective efficacy of the chelator-nanoparticle
systems and to evaluate their toxicity and to optimize their capability to cross the blood brain
barrier.
Keywords: Neurodegenerative, metal chelation, nanoparticles, blood brain barrier.
[Full Text Article]